CAM
ITRM

Cormorant Asset Management’s Iterum Therapeutics ITRM Stock Holding History

Cormorant Asset Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,426
Closed -$2.34M – 74
2019
Q3 		$2.34M Hold
26,426
– – 0.14% 65
2019
Q2 		$2.73M Sell
26,426
-127
-0.5% -$14.1K 0.16% 65
2019
Q1 		$3.2M Sell
26,553
-4,514
-15% -$414K 0.22% 56
2018
Q4 		$2.33M Sell
31,067
-731
-2% -$69.2K 0.19% 62
2018
Q3 		$3.2M Sell
31,798
-1,535
-5% -$200K 0.21% 57
2018
Q2 		$5.45M Buy
+33,333
New +$6.02M 0.4% 47

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Cormorant Asset Management's ITRM Position: Q4 2019 in Review

Cormorant Asset Management sold out of Iterum Therapeutics (ITRM) in Q4 2019, closing a stake of 26,426 shares — an estimated $2.34M sold.

Cormorant Asset Management first reported a position in ITRM in Q2 2018 and held it in 6 quarters. The position peaked at $5.45M in Q2 2018. 13 funds tracked by Wall St. Rank hold ITRM as of Q4 2019.

  • Cormorant Asset Management reported no remaining Iterum Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Cormorant Asset Management sold 26,426 Iterum Therapeutics shares in Q4 2019, an estimated $2.34M.
  • Cormorant Asset Management first reported a position in Iterum Therapeutics in Q2 2018 and held it in 6 quarters.
  • Cormorant Asset Management's Iterum Therapeutics position peaked at $5.45M in Q2 2018.
  • 13 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.